Shubhadeep D. Sinha

Featured in: Favicon

Articles

Polmacoxib 2mg in patients with mild to moderate idiopathic osteoarthritis of hip/knee-a randomized, double-anonymous study

Nov 15, 2024 | tandfonline.com | Arun Kumar Sharma |Srinivas Reddy Devireddy |Shubhadeep D. Sinha |Tadikonda Bhavani Prasad

ABSTRACTAim Polmacoxib, a new COX-2 inhibitor with carbonic anhydrase (CA) inhibitory action, is expected to help minimize the adverse effects associated with other NSAIDs, like GI (gastrointestinal) and CV (cardiovascular) system- related issues.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.